Contacts, documents and full notice history are available with a subscription.
Special Notice NONE Expired 1 notice

Notice of Intent to Sole Source Vitrolife HT942525Q0630

Solicitation HT942525Q0630 Copied Notice ID 7eaccff33c3b4e9cb625fd5a955735c6 Copied DEPT OF DEFENSE — ARMY MED RES ACQ ACTIVITY
SAM.gov
Posted
Jun 30, 2025
Deadline
Jul 15, 2025
Set-aside
NONE
NAICS
325413
PSC
6550

Summary

AI-generated · Aug 25, 2025

A sole-source, firm-fixed-price contract is being pursued with Vitrolife, Inc. for a Viscosity Treatment System, Enhance-S Plus Set, Sperm Wash Medium, and the 20 μm, 2-chamber MicroCell used for fertility testing to support pre-chemotherapy screening and comprehensive infertility investigations for Naval Medical Center San Diego patients. Vitrolife is identified as the only vendor able to meet the current needs, and using any other reagents or components would require thorough investigation, reassessment, and revalidation under CLSI and CAP accreditation, potentially delaying testing and affecting existing systems.

This is not a competitive solicitation; it is a notice of intent to award a sole-source contract. Other firms that can meet the requirements may identify their interest and capability by contacting the designated Government point of contact.

The Defense Health Agency (DHA) U.S. Army Medical Research Acquisition Activity (USAMRAA) intends to award a Firm Fixed Price sole source contract on behalf of the Naval Medical Center San Diego (NMSCD) to Vitrolife, Inc., under the authority FAR 13.106-1(b)(1): For purchases not exceeding the simplified acquisition threshold (SAT), only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name, or industrial mobilization). This requirement is for a Viscosity Treatment System, Enhance-S Plus Set, Sperm Wash Medium and the 20 um, 2-chamber MicroCell for fertility testing. These reagents and supplies required provide pre-chemotherapy screening and comprehensive infertility investigation for NMCSD patients. Vitrolife, Inc. is the only vendor able to provide the reagents and supplies that can meet the current needs of NMCSD. Use of Vitrolife Inc. reagents and supplies will ensure the continuity of testing for the investigation of current conditions and or functions of existing systems. Any change to the product necessitates thorough investigation, assessment and approval of individual components utilized in the testing procedure in accordance with the Clinical and Laboratory Standards Institute (CLSI) and College of American Pathologist (CAP) accreditation requirements. Current Vitrolife system components in use are FDA approved, have been assessed, validated and approved for use, hence ready for use and require no further assessment for continued use beyond applicable accreditation requirements. Other reagents are available, however the methodology, kit/reagent complexity and/or protocols will require reassessment and revalidation if introduced. Modification of procedures will result in delays and/or necessity to refer patients to outside networks for service. This is a notice of intent to issue a contract on a Sole Source basis. This notice of intent is NOT a request for quotations (RFQ). Any other firms desiring consideration must fully identify their interest and capability to provide these services to the individual listed below. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Interested persons may identify their interest in writing, to the Government point of contact. Responses to this notice must be received no later than 2:00 PM Eastern Standard Time, 15 July 2025. The point of contact for this action is James Cheng, james.cheng1.civ@health.mil. No telephone requests will be honored.

From Special Notice posted on Jun 30, 2025

Notice history

1
  1. Special Notice LATEST Posted Jun 30, 2025

Details

Solicitation number HT942525Q0630
Notice ID 7eaccff33c3b4e9cb625fd5a955735c6
Notice type Special Notice
Product / Service (PSC) 6550
NAICS 325413
Set-aside No Set aside used
Place of performance San Diego, California
Archive date Jul 30, 2025

Award Information

Not yet awarded

Documents

No files available

View on SAM.gov

Contacts

primary
James Cheng

Email

Phone

Agency

DEPT OF DEFENSE
DEFENSE HEALTH AGENCY (DHA)
ARMY MED RES ACQ ACTIVITY

Place of Performance

San Diego, California 92134
USA

Dates

Posted Jun 30, 2025 1 year ago
Last Updated Aug 06, 2026 1 day ago
Due Jul 15, 2025 1 year ago